Post-Infectious IBS: When IBS Starts After Food Poisoning or COVID

Post-infectious IBS (PI-IBS) is irritable bowel syndrome that starts after an episode of bacterial, viral, or parasitic gastroenteritis and persists well after the acute infection has resolved. Systematic reviews estimate 6-17% of adults who have a bacterial gut infection go on to meet IBS criteria within 12 months. Rising post-COVID cases are extending the list of triggering infections. Hypnotherapy is complementary care, not a substitute for medical diagnosis or treatment, and is not a regulated health profession in Alberta.

Post-infectious IBS is the clinical term for irritable bowel syndrome that begins after a discrete episode of acute gastroenteritis and persists well after the original infection has cleared. It is classified as IBS in the full sense: it meets the same Rome IV symptom criteria as any other IBS subtype, including recurrent abdominal pain associated with defecation and altered stool form or frequency. What makes it “post-infectious” is the datable trigger event and the specific biological fingerprint that infection-triggered IBS tends to leave behind.

Under the Rome IV framework, IBS is categorised as a disorder of gut-brain interaction (DGBI) rather than a strictly peripheral gut disorder. In PI-IBS, the chain of events looks roughly like this: an acute infection produces intense gut inflammation, immune activation, motility disruption, microbiome shift, and sensory amplification; the acute infection resolves; the gut lining heals and looks structurally normal again; but the nervous-system calibration, the microbiome, the immune tone, and the enteric nerve reactivity do not fully reset. The gut looks fine on imaging, but the signalling about the gut — the visceral hypersensitivity that is the core IBS mechanism — has been calibrated up by the original event and stays up.

Two framings patients find clarifying:

• The fire-alarm framing: the infection set off every alarm in the building. The fire is out, the damage has been cleaned up, and the structure looks fine. But the alarm system has been recalibrated to the emergency and keeps triggering at a much lower threshold.
• The echo framing: the infection was the original event. PI-IBS is the echo that keeps reverberating through the gut-brain axis for months or years after the source has gone.

PI-IBS is also a key part of the answer to one of the most common patient questions — “why did my IBS start?” For people who can point to a specific food poisoning episode, a stomach bug, a round of travellers' diarrhoea, or a COVID infection and say “my gut has not been the same since,” post-infectious IBS is usually the best-fitting explanation. For broader context on the other pathways into IBS, see what causes IBS.

Post-infectious IBS is not rare. Halvorson and colleagues' systematic reviews of PI-IBS epidemiology consistently estimate that 6-17% of adults who experience a bacterial gastroenteritis meet IBS criteria within 12 months of the acute infection. The wide range reflects genuine differences between studies — population, specific pathogen, severity, baseline IBS prevalence, and how strictly the IBS diagnosis was applied all matter — but the headline finding is consistent across decades of work: gut infections substantially raise the risk of subsequent IBS.

Several aspects of the epidemiology are worth highlighting:

• Elevated relative risk. Across studies, the risk of developing IBS in the year after a gastroenteritis is typically 4-6 times higher than in matched, non-infected controls. The absolute baseline risk is small, but a 4-6x multiplier is a substantial shift.
• Pathogen matters. Bacterial infections (Campylobacter, Salmonella, Shigella, E. coli) have historically been the best-characterised triggers. Viral infections (norovirus, rotavirus, more recently SARS-CoV-2) and parasitic infections (Giardia) also trigger PI-IBS. The per-pathogen rate varies.
• Severity and duration matter. Longer, more severe acute infections carry higher PI-IBS risk. Hospitalised gastroenteritis carries higher risk than self-limiting gastroenteritis managed at home.
• Persistence at 2 years is substantial. Following PI-IBS cohorts over time, roughly 40-60% of patients still meet IBS criteria at 2-year follow-up. That is not permanent — the rate continues to decline beyond 2 years — but it is substantial enough that waiting indefinitely to see whether symptoms resolve on their own is not always the best strategy, particularly where symptoms are disruptive to quality of life.
• Post-COVID PI-IBS is rising. Since 2020, emerging COVID-gut literature has added SARS-CoV-2 to the list of recognised PI-IBS triggers, with a non-trivial subset of COVID-19 patients developing persistent IBS-type symptoms after the acute infection has resolved. Precise rates are still being characterised in ongoing research.

The PI-IBS trigger list is not narrow. What unites these infections is the acute gut inflammation, immune activation, and microbiome disruption they produce — not the specific pathogen itself. Any gastroenteritis severe enough to produce substantial acute gut symptoms can, in a subset of patients, leave PI-IBS behind.

Bacterial triggers

Bacterial gastroenteritis has been the best-characterised PI-IBS trigger category for decades. The classic offenders are Campylobacter, Salmonella, Shigella, and pathogenic strains of E. coli. In cohort studies following outbreak-associated gastroenteritis, per-pathogen PI-IBS rates of 10-17% within 12 months are not uncommon — toward the higher end of the overall 6-17% range. Bacterial infections tend to produce longer, more intense acute illness and more severe mucosal inflammation than viral gastroenteritis, which is thought to contribute to the higher rate.

Viral triggers

Viral gastroenteritis — particularly norovirus and rotavirus — has also been documented as a PI-IBS trigger. Norovirus outbreaks (cruise ships, care homes, daycares) have been followed by measurable rises in subsequent IBS. Per-infection rates are generally lower than for the classic bacterial triggers, but the sheer frequency of norovirus exposure in the general population means it contributes meaningfully to overall PI-IBS incidence.

SARS-CoV-2 / COVID-19

Since 2020, emerging COVID-gut literature has progressively added SARS-CoV-2 to the PI-IBS trigger list. The mechanism has a concrete biological basis: SARS-CoV-2 binds the ACE2 receptor, and ACE2 is heavily expressed in the gut lining as well as the respiratory tract. Acute COVID-19 frequently produces gut symptoms — diarrhoea, cramping, nausea — during the active infection phase, and a non-trivial subset of patients report new-onset or persistent gut symptoms that meet IBS criteria well after the acute illness has resolved. The precise epidemiological rates are still being characterised, and this is treated as emerging rather than fully consolidated literature, but the mechanism and the clinical pattern are well enough established that COVID-19 is reasonably grouped with the other PI-IBS triggers in 2026 practice.

Parasitic triggers

Parasitic infections — Giardia in particular, with additional documentation for Cryptosporidium and amoebiasis — can trigger PI-IBS as well. The classic presentation here is travel-associated: a trip abroad, a waterborne exposure, a bout of dysentery, apparently successful eradication treatment, and then persistent bowel symptoms for months or years afterward. The Bergen giardiasis outbreak in Norway is one of the more extensively studied natural experiments showing long-term PI-IBS rates after a defined parasitic exposure.

It is worth noting that the specific pathogen matters less for treatment than the fact of infection-triggered onset. The downstream mechanism — altered gut-brain axis calibration — is broadly similar across triggers, and so is the treatment toolkit.

PI-IBS is not one mechanism. It is three infection-triggered processes that emerge during the acute gastroenteritis and do not fully resolve once the infection clears. Understanding each matters because different treatments target different layers, and most PI-IBS patients benefit from interventions hitting more than one.

1. Microbiome disruption

Acute gastroenteritis produces a major disturbance in the gut microbiome. The invading pathogen competes with the native population; antibiotic treatment (when used) further reduces diversity; diarrhoea mechanically washes out a fraction of the luminal microbiome; and the post-infection environment favours some species over others. In most people, the microbiome substantially restores itself within weeks to months. In PI-IBS, the restoration is incomplete or skewed. Reduced diversity, altered Firmicutes:Bacteroidetes ratio, overgrowth of pro-inflammatory species, and (in a subset) small intestinal bacterial overgrowth (SIBO) have all been documented. A dysregulated microbiome produces altered short-chain fatty acid production, altered tryptophan and serotonin handling, and altered gut motility — all of which feed into the other mechanisms.

2. Visceral hypersensitivity

Acute infection acutely sensitises the visceral nerves. In most cases the sensitization reverses with the infection; in PI-IBS it does not. Research biopsies of PI-IBS patients have shown increased enterochromaffin cell density, altered serotonin handling, increased intraepithelial lymphocytes, and altered enteric nervous system reactivity persisting well beyond the acute illness. The result is a gut that registers normal-strength signals (routine distension, normal peristalsis, mild fermentation) as painful because the peripheral and central processing has been calibrated up. This is the mechanism that most directly drives the day-to-day symptom experience and is the primary target of gut-directed hypnotherapy. For a deeper treatment of this mechanism, see visceral hypersensitivity.

3. Low-grade persistent inflammation

Healthy gut lining returns to macroscopic normality after most infections. Research in PI-IBS has shown that a subset retains low-grade, microscopic inflammation — elevated mucosal cytokines, increased immune cell infiltrates, and altered tight-junction protein expression (a surrogate for mildly increased intestinal permeability). This is well below the threshold of inflammatory bowel disease and typically not visible on routine imaging or biopsy unless specifically looked for. But it can be enough to keep the peripheral nerves in an over-reactive state, which in turn keeps the central sensitization reinforced, which keeps the symptom pattern going.

The three mechanisms are not independent. They form a self-reinforcing loop: a disrupted microbiome produces metabolites that favour low-grade immune activation; immune activation sensitises visceral nerves; sensitised nerves alter motility and secretion in ways that favour the disrupted microbiome. Breaking the loop is part of what successful treatment has to do. For the broader context on how the gut-brain axis integrates all of this, see the gut-brain connection.

PI-IBS and regular IBS share more than they differ. Both meet the Rome IV IBS criteria. Both share visceral hypersensitivity as the core mechanism. Both respond to the same core treatment toolkit (gut-directed hypnotherapy, CBT-for-IBS, low-FODMAP, low-dose tricyclic antidepressants). The distinction is worth making, though, because a few differences have real clinical implications.

Onset timing and event

The defining PI-IBS feature is a clearly datable onset event: a specific acute infection that preceded the chronic symptoms. Patients can usually identify the month, sometimes the week. Regular IBS typically has a more gradual onset, often over months or years, without a single pinpoint trigger event — or with a life-stress event (bereavement, job change, divorce) rather than an infection as the apparent precipitant.

Subtype distribution

PI-IBS most often presents as IBS-D (diarrhoea-predominant) initially, reflecting the diarrhoeal pattern of the original infection. Some cases evolve toward IBS-M (mixed) over time. IBS-C (constipation-predominant) is relatively less common in PI-IBS than in regular IBS populations. In regular IBS, all three subtypes are well-represented.

Biological fingerprint

Research biopsies of PI-IBS patients have shown some distinctive findings, especially in the first year or two post-infection: increased enterochromaffin cell density, altered serotonin handling, increased intraepithelial lymphocytes, and more evidence of low-grade inflammation. These findings are not routinely tested for in my hypnotherapy practice because they do not usually change treatment decisions, but they do support the mechanism model and help explain why PI-IBS often fades over time as these changes gradually normalise.

Prognosis

PI-IBS has a relatively more optimistic long-term prognosis than some other forms of IBS. A substantial proportion resolves or markedly improves within 6-24 months, and even among the 40-60% still symptomatic at 2 years, gradual improvement continues beyond that window. Regular IBS with onset in early life or tied to early-life adversity tends to have a more chronic trajectory on average, though this is a generalisation with many exceptions in both directions.

Family history signal

Regular IBS carries a stronger family history signal (heritable component roughly in the order of 30-40% in twin studies). PI-IBS is more dominantly environmental in origin — the acute infection is the main driver, though genetic background influences who develops PI-IBS after a given infection.

None of these differences is absolute. PI-IBS and regular IBS exist on a spectrum rather than in distinct categories, and some patients have a mixed picture (an underlying functional tendency plus an infection-triggered worsening). The clinical utility of the distinction is mainly in counselling and expectation-setting. For a PI-IBS patient, the clear trigger event and the reasonably optimistic long-term trajectory are concrete, reassuring elements of the picture.

The timeline for PI-IBS is one of the more hopeful aspects of the clinical picture, though the arc is slower than most patients hope for at diagnosis.

• 0-3 months post-infection: acute gastroenteritis, acute symptoms, and immune-resolution phase. Gut function is often disrupted, but a chronic pattern has not yet established. Most people recover fully during this window.
• 1-6 months post-infection: the typical PI-IBS onset window. Symptoms re-emerge after a period of apparent recovery, or never fully resolved. A Rome IV IBS diagnosis usually becomes appropriate somewhere in this window after structural disease has been excluded.
• 6-24 months post-infection: the typical recovery window. A substantial proportion of PI-IBS cases resolve or markedly improve during this period, either with active treatment or with time alone. The trajectory is usually gradual rather than sudden.
• At 2 years: roughly 40-60% of PI-IBS patients still meet IBS criteria. This is meaningful, but it also means 40-60% have substantially improved or resolved.
• Beyond 2 years: continued slow improvement in many, with a smaller proportion settling into a long-term chronic IBS pattern. Targeted treatment at any point in this window — gut-directed hypnotherapy, CBT-for-IBS, dietary work, physician-managed medications — can accelerate recovery meaningfully, including for cases that have been present for years.

Several factors appear to predict more rapid recovery: shorter duration of the original acute illness, lower baseline anxiety and stress, absence of mood disorder during the acute infection, female hormonal status favourable at the time of infection, younger age, and earlier engagement with targeted treatment. Predictors of longer persistence include severe or prolonged original illness, high baseline anxiety, pre-existing depression, smoking, and waiting a long time before seeking targeted treatment.

The practical clinical implication: PI-IBS is not a sentence. Most cases improve substantially, and active treatment at any point in the trajectory can accelerate that. Waiting years to see whether symptoms resolve on their own is rarely the best strategy if symptoms are meaningfully affecting quality of life. For a broader framing on realistic expectations for treatment, see how many sessions of gut-directed hypnotherapy.

PI-IBS is treated within the broader IBS treatment framework. The good news is that the evidence base for the main IBS treatments applies directly to PI-IBS, and the mechanism match for central-acting interventions like gut-directed hypnotherapy is particularly strong.

Gut-directed hypnotherapy (central, mechanism-matched)

Gut-directed hypnotherapy is the intervention with the strongest evidence base for the visceral hypersensitivity that sits at the core of PI-IBS. Miller 2015 (PMID 25736234), an audit of 1,000 consecutive adult IBS patients treated on the Manchester Protocol, reported 76% response with sustained benefit at 5-year follow-up. The cohort was a broad IBS population that included PI-IBS patients. Peters 2016 (PMID 27397586) directly compared gut-directed hypnotherapy to the low-FODMAP diet in a randomised design and found them equivalent on GI symptom outcomes, with hypnotherapy superior on psychological outcomes. The mechanism match for PI-IBS is strong because the dominant pathophysiology — infection-triggered peripheral and central sensitization — is exactly what gut-directed hypnotherapy targets. This practice follows the Manchester Protocol as its clinical reference framework. For a deeper treatment, see hypnotherapy for IBS and what is gut-directed hypnotherapy.

Low-FODMAP dietary protocol (peripheral)

The Monash University low-FODMAP protocol reduces peripheral fermentable load, giving a sensitized gut less of the input it over-reacts to. In PI-IBS, where microbiome disruption is one of the three core mechanisms, reducing fermentable substrate can produce meaningful symptom relief. Peters 2016 (PMID 27397586) found low-FODMAP equivalent to gut-directed hypnotherapy on GI outcomes in a randomised design. Best run with a dietitian, and the reintroduction phase is as important as the elimination phase. For a head-to-head comparison, see low-FODMAP vs hypnotherapy.

CBT for IBS (central)

Cognitive behavioural therapy adapted specifically for IBS targets the cognitive, attentional, and behavioural amplification of visceral sensations. Multiple RCTs and meta-analyses support its efficacy in IBS, with effect sizes comparable to gut-directed hypnotherapy. It is a reasonable alternative or complement to GDH — some patients prefer the active-problem-solving style of CBT, others prefer the experiential, state-change style of hypnotherapy.

Low-dose tricyclic antidepressants (physician-managed)

Low-dose TCAs (amitriptyline, nortriptyline, desipramine at 10-50 mg nightly, below the antidepressant dose) have decades of evidence for visceral pain and are a standard physician-prescribed option in refractory IBS and PI-IBS presentations with prominent pain. The mechanism is primarily analgesic rather than mood-altering at these doses. A physician-managed decision with consideration of side-effect profile.

Targeted antibiotic treatment if SIBO is present

A subset of PI-IBS patients have small intestinal bacterial overgrowth (SIBO) as part of the microbiome disruption picture. Where SIBO is documented on appropriate testing, rifaximin is the most commonly used targeted antibiotic and has evidence in SIBO-associated IBS. A physician-managed decision; not a first-line empirical treatment without a SIBO workup.

Supportive lifestyle interventions

Sleep regularisation, stress management, regular exercise, vagal tone work (breathwork, mindfulness), and avoiding unnecessary antibiotics support all of the above interventions. Effect sizes as stand-alones are typically smaller, but they compound with the targeted treatments and make the overall trajectory more favourable. For broader context on the anxiety-gut connection that commonly overlaps with PI-IBS, see IBS and anxiety.

In practice, the best PI-IBS outcomes tend to come from a combined approach matched to the dominant mechanism profile in the individual case. A PI-IBS patient with prominent pain and strong visceral-sensitization features often benefits most from gut-directed hypnotherapy as the anchor of treatment, with dietary work and lifestyle support reinforcing it. A PI-IBS patient with prominent bloating and evidence of SIBO may benefit from peripheral-first treatment (rifaximin, dietary modification) with GDH or CBT layered in once the peripheral driver is addressed. A 15-minute clinical intake is usually enough to work out which sequence is likely to help.

Since 2020, a substantial and growing body of emerging COVID-gut literature has added SARS-CoV-2 to the PI-IBS trigger list. This is worth its own section because patterns and open questions differ somewhat from the classic bacterial PI-IBS model.

The mechanism has a specific biological anchor

SARS-CoV-2 binds the ACE2 receptor to enter host cells. ACE2 is heavily expressed in the gut lining (particularly in the small intestine) as well as in the respiratory tract. During acute COVID-19 infection, a meaningful proportion of patients have gut symptoms — diarrhoea, nausea, abdominal pain, loss of appetite — reflecting direct viral activity in the gut. The acute gut phase is well-documented.

Persistent post-acute gut symptoms are part of long-COVID

A subset of COVID-19 patients report gut symptoms that persist well beyond the acute infection, often as part of the broader long-COVID (post-acute sequelae of SARS-CoV-2) picture. Symptoms include new or worsened diarrhoea, constipation, bloating, abdominal pain, urgency, and reflux. In many cases, these symptoms meet the Rome IV IBS criteria when they persist. Dysmotility — abnormal gut motility patterns that can mimic or contribute to IBS — is also documented in a subset.

Precise rates are still being characterised

The epidemiological rates for post-COVID IBS specifically are still being worked out in ongoing research. Estimates vary substantially between studies depending on the population, the time since infection, whether post-COVID IBS was the pre-specified outcome, and what diagnostic criteria were applied. What is consistent across the emerging literature is that a meaningful and non-trivial subset of COVID-19 patients develop persistent gut symptoms compatible with PI-IBS. Precise percentages should be treated as provisional until the evidence consolidates. We are deliberately not citing specific figures here, as the numbers are still being refined.

Clinical pattern overlaps with classic PI-IBS

Clinically, post-COVID IBS presents very similarly to other forms of PI-IBS: a clear trigger infection, a period of apparent recovery in many cases, re-emergence of symptoms, and a Rome IV-compatible chronic pattern. The treatment approach is the same as for other PI-IBS triggers: physician-led workup, red-flag screening, Rome IV confirmation, then targeted treatment matched to the dominant mechanism profile. Gut-directed hypnotherapy, low-FODMAP work, CBT-for-IBS, and low-dose TCAs all apply.

A few post-COVID-specific considerations

Two features of the post-COVID picture warrant extra attention:

• Fatigue and autonomic dysfunction overlap. Long-COVID often includes fatigue, post-exertional malaise, dysautonomia, and orthostatic intolerance. These can interact with gut symptoms in ways that are not typical of classic bacterial PI-IBS. Treatment planning often needs to factor in pacing, energy management, and autonomic-nervous-system support alongside the gut-focused work.
• The broader long-COVID picture may need multidisciplinary input. A long-COVID clinic or internal medicine specialist experienced with post-acute COVID sequelae is often a valuable addition to the care team for patients with complex multi-system symptoms. Gut-directed hypnotherapy sits alongside, not instead of, that broader care.

The framing that holds up well in 2026: if your gut has not been the same since COVID-19, that is a recognised and increasingly characterised clinical pattern, and the same evidence-based PI-IBS toolkit applies. The mechanism is similar enough to classic PI-IBS that the treatment response patterns translate. Longer- term outcome data specific to post-COVID IBS is still accruing; what is available is broadly reassuring on the trajectory while warranting a careful clinical approach for more complex multi-system presentations.

PI-IBS is a diagnosis made after structural disease has been excluded and the Rome IV IBS criteria are met positively. That means the baseline starting point for any new or changed gut symptom pattern should be a physician-led assessment. Most PI-IBS cases are managed by a family physician, sometimes with a gastroenterology referral. Specific features should trigger prompt specialist evaluation rather than watchful waiting:

• Blood in stool — visible blood, dark or tarry stools, or positive faecal occult blood testing. Requires prompt assessment to exclude inflammatory bowel disease, colorectal pathology, and other structural causes.
• Unintentional weight loss — more than a few kilograms without deliberate diet change. Especially important with other alarm features.
• Fevers or night sweats — persistent systemic symptoms are not typical of IBS and suggest an alternative or additional diagnosis.
• Symptoms waking you from sleep — classic IBS symptoms are typically quiescent during sleep. Nocturnal diarrhoea or pain that consistently wakes you is not typical of functional disease.
• New-onset symptoms over age 50 without prior GI history. The pre-test probability of structural disease shifts upward with age and warrants a more thorough workup, typically including colonoscopy.
• Family history of inflammatory bowel disease, celiac disease, or colorectal cancer — raises the pre-test probability for those conditions and should lower the threshold for specialist evaluation and appropriate screening.
• Severe or rapidly worsening pain, particularly pain that is localising, persistent, and associated with other systemic features.
• Persistent diarrhoea beyond the expected post-infection window — sustained diarrhoea lasting months post-infection warrants workup for persistent infection (C. difficile, Giardia, parasitic causes), inflammatory bowel disease, microscopic colitis, and bile acid malabsorption.
• Failure to improve with first-line management after 3-6 months of appropriate treatment — a reasonable point to reassess the diagnosis and consider specialist input.

Hypnotherapy is complementary care, not a substitute for medical diagnosis or treatment. It is not a regulated health profession in Alberta. A physician-led workup to rule out structural disease and a Rome IV-confirmed IBS diagnosis should always precede or run alongside any hypnotherapy program. Gut-directed hypnotherapy does not treat inflammatory bowel disease, colorectal pathology, celiac disease, or persistent infection — it treats the dysregulated signalling that is the defining feature of IBS after structural causes have been excluded.

Yes, PI-IBS can become chronic — but the framing that matters most for patients is that chronic does not mean untreatable, and most cases improve substantially over time with or without active treatment. Targeted treatment at any point in the trajectory tends to accelerate recovery, including for cases that have been present for years.

A few key points to hold simultaneously:

• A majority of PI-IBS cases resolve or markedly improve within the first 6-24 months. Most people do get better.
• Roughly 40-60% are still meeting IBS criteria at 2 years. That is substantial but it also means 40-60% are substantially better.
• Beyond 2 years, slow continued improvement is common; a smaller proportion settles into a long-term chronic IBS pattern.
• The evidence base for gut-directed hypnotherapy, CBT-for-IBS, low-FODMAP, and low-dose TCAs applies directly to PI-IBS and produces meaningful improvements in responders regardless of how long symptoms have been present.
• Miller 2015's 5-year durability finding — sustained benefit at 5-year follow-up in the majority of gut-directed hypnotherapy responders — is one of the more impressive long-term outcome datasets in the functional GI literature, and applies to PI-IBS patients within the broader IBS cohort studied.
• The single most important reframe for most PI-IBS patients is this: your gut is not broken, your nervous system has been miscalibrated by an infection, and miscalibration can be retrained. That is not optimism; it is what the research consistently shows.

The practical implication: waiting indefinitely to see whether PI-IBS resolves on its own is not always the best approach, especially when symptoms are meaningfully affecting daily life. Starting a targeted treatment within the first year or two of onset often produces faster recovery than waiting several years and then starting. That said, it is never too late. People who have had PI-IBS for 5 or 10 years still respond to gut-directed hypnotherapy and other targeted treatments at rates broadly similar to people who start treatment within the first year.

Starting points depend on the individual picture. For most PI-IBS patients with clear visceral-hypersensitivity features, gut-directed hypnotherapy anchored by a Rome IV diagnosis and physician-led red-flag screen is a reasonable first move. Dietary work, lifestyle support, and (in some cases) physician-managed medication layer in as needed. For broader cost and session-number context, see gut-directed hypnotherapy cost in Calgary and how many sessions of gut-directed hypnotherapy. For a broader IBS treatment comparison, see IBS treatment comparison 2026.

Related reading: Visceral hypersensitivity · The gut-brain connection · What causes IBS · Hypnotherapy for IBS · IBS and anxiety · Low-FODMAP vs hypnotherapy · Hypnotherapy for SIBO